Literature DB >> 15547782

Sigma receptors and sigma ligands: background to a pharmacological enigma.

B E Leonard1.   

Abstract

Although it is now well established that the sigma receptors are distinct from neurotransmitter, neuropeptide and steroid receptors, their precise physiological role, and possible involvement in the pathology of neurological and psychiatric disorders, remains an enigma. The purpose of this short review is to provide a basis upon which to explain the pharmacological properties of such a diverse group of drugs as the antidepressants, antipsychotics and neuroprotective agents. However, a greater understanding of the importance of the sigma receptors will depend on the development of more potent and selective sigma agonists and antagonists if the therapeutic potential of the sigma receptors is to be fully realised.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547782     DOI: 10.1055/s-2004-832674

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

1.  Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor.

Authors:  Arindam Pal; Uyen B Chu; Subramaniam Ramachandran; David Grawoig; Lian-Wang Guo; Abdol R Hajipour; Arnold E Ruoho
Journal:  J Biol Chem       Date:  2008-05-07       Impact factor: 5.157

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

3.  Synthesis and receptor profiling of Stemona alkaloid analogues reveal a potent class of sigma ligands.

Authors:  Kevin J Frankowski; Vincent Setola; Jon M Evans; Ben Neuenswander; Bryan L Roth; Jeffrey Aubé
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

4.  The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates.

Authors:  Aladdin Riad; Zsofia Lengyel-Zhand; Chenbo Zeng; Chi-Chang Weng; Virginia M-Y Lee; John Q Trojanowski; Robert H Mach
Journal:  Mol Neurobiol       Date:  2020-06-23       Impact factor: 5.590

Review 5.  A role for sigma receptors in stimulant self-administration and addiction.

Authors:  Jonathan L Katz; Weimin C Hong; Takato Hiranita; Tsung-Ping Su
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

Review 6.  Ketamine in pain management.

Authors:  Jan Persson
Journal:  CNS Neurosci Ther       Date:  2013-05-11       Impact factor: 5.243

7.  Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine.

Authors:  Michele Fornaro
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-29       Impact factor: 2.570

8.  A Role for Sigma Receptors in Stimulant Self Administration and Addiction.

Authors:  Jonathan L Katz; Tsung-Ping Su; Takato Hiranita; Teruo Hayashi; Gianluigi Tanda; Theresa Kopajtic; Shang-Yi Tsai
Journal:  Pharmaceuticals (Basel)       Date:  2011

9.  Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.

Authors:  Nicholas J Izzo; Jinbin Xu; Chenbo Zeng; Molly J Kirk; Kelsie Mozzoni; Colleen Silky; Courtney Rehak; Raymond Yurko; Gary Look; Gilbert Rishton; Hank Safferstein; Carlos Cruchaga; Alison Goate; Michael A Cahill; Ottavio Arancio; Robert H Mach; Rolf Craven; Elizabeth Head; Harry LeVine; Tara L Spires-Jones; Susan M Catalano
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

10.  4-aroylpiperidines and 4-(α-hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studies.

Authors:  Hermia N Ikome; Fidele Ntie-Kang; Moses N Ngemenya; Zhude Tu; Robert H Mach; Simon M N Efange
Journal:  Chem Cent J       Date:  2016-08-23       Impact factor: 4.215

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.